Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: Further evidence for melanocytic differentiation

Scott R. Granter, Katherine N. Weilbaecher, Catherine Quigley, Christopher D.M. Fletcher, David E. Fisher

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Microphthalmia transcription factor, a melanocytic nuclear protein critical for the embryonic development and postnatal viability of melanocytes, is a master regulator in modulating extracellular signals. Recently, microphthalmia transcription factor expression was shown to be both a sensitive and specific marker of epithelioid melanoma. We investigated the sensitivity of D5, an anti-microphthalmia transcription factor antibody, for diagnosis of clear cell sarcoma (also known as malignant melanoma of soft parts). Immunoreactivity in a nuclear pattern for D5 was present in 8 of 12 (75%) tumors. D5 staining was strong in three tumors, moderate in two, and weak in three. S-100 protein expression was seen in all 12 cases that had clear cell sarcoma examined. HMB-45 staining was seen in 11 of 12 (92%) tumors. Focal Melan-A positivity was seen in 3 of 7 (43%) tumors. Although D5 was shown in a previous study to be a highly sensitive and specific marker for epithelioid melanomas, the results of this study expand the spectrum of tumors showing immunoreactivity for D5. D5 immunoreactivity in clear cell sarcoma provides further evidence for melanocytic differentiation in this unusual tumor.

Original languageEnglish
Pages (from-to)6-9
Number of pages4
JournalModern Pathology
Volume14
Issue number1
DOIs
StatePublished - Feb 6 2001

Keywords

  • Clear cell sarcoma
  • D5 immunoreactivity
  • Melanoma
  • Microphthalmia transcription factor

Fingerprint

Dive into the research topics of 'Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: Further evidence for melanocytic differentiation'. Together they form a unique fingerprint.

Cite this